Pan-FGFR kinase inhibitor (FGFRi) treatment (with pemigatinib, infigratinib, or futibatinib) improves outcomes of patients with FGFR2 + ICC, leading to the FDA approval of these agents in the second-line setting and beyond13–15. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.